🇺🇸

Index Intelligence

· daily

S&P 500 Industrials Sector SEC Filings — May 01, 2026

The 50 filings reveal mixed Q1 2026 performance across S&P 500 Industrials and adjacent sectors, with 14/22 Q1 reporters showing YoY revenue growth averaging +6.2% (e.g., Cboe +29%, Zeta +49.9%, Parker-Hannifin +8.3%), but 8 experiencing declines averaging -15.4% (e.g., Wabash -20.4%, Matthews -39.5%, Dream Finders -10.3%), driven by transportation softening and divestitures. EBITDA and operating income trends are bifurcated: 9 companies grew EBITDA/Adj EBITDA +15% avg (Shentel +15%, Ares record highs), while margins compressed -120 bps avg in 7/15 cases amid restructuring and capex. Capital allocation shines with $2.5B Verizon repurchases, $214M C.H. Robinson buybacks, $40M Fulgent repurchases, and dividend declarations/increases (Ares $1.35, Federal Realty $1.13 up from $1.10). M&A/refinancing activity bullish: Herbalife $45M annual interest savings, UWM revised Two Harbors offer, Stock Yards acquisition adding branches. Guidance mostly stable/reiterated (Shentel $370-377M rev), with raises (Cboe low double-digits to mid-teens, Federal Realty FFO $7.46-7.55). 13F filings (12/50) show neutral institutional positioning tilted to tech/ETFs over pure industrials, with GE holding Beta Technologies/Hyliion. Implications: Cyclical industrials stabilizing via backlogs (Wabash +$132M), but watch transportation losses; prioritize capital returners for near-term alpha.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 01, 2026

S&P 500 Energy sector filings reveal mixed Q1 2026 results for majors ExxonMobil and Chevron, with GAAP earnings declining sharply YoY (XOM -46%, CVX from $3.5B to $2.2B) due to timing effects, legal reserves, and downstream losses, but offset by strong production growth (CVX worldwide +15% to 3,858 MBOED, US +24% to 2,024 MBOED; XOM record Guyana output) and robust shareholder returns (XOM $9.2B distributions incl. $4.9B buybacks; CVX $6.0B incl. $2.5B repurchases). Marathon Petroleum's annual meeting approved directors, auditor, and exec comp but rejected governance reforms needing 80% votes, signaling entrenched board structure. Robert Half (non-energy outlier) shows sharp declines (revenues -3.8% YoY, net income -20.5% YoY). Portfolio-level trends include upstream strength vs. downstream weakness, sustained capital returns amid earnings volatility, and capex guidance stability at XOM ($27-29B FY2026). Implications: Favor production-focused longs, monitor downstream recovery; governance stasis at MPC may cap upside.

1 high priority 3 medium 4 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 01, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily Q1 2026 earnings, 8-Ks, and proxies), a dominant theme is robust revenue growth averaging 15-20% YoY in 18/22 reporting companies (e.g., Cboe +29%, Oppenheimer +21%, Ryan Specialty +15%), driven by investment banking, data services, and M&A, though profitability remains mixed due to one-offs like legal accruals ($70M at Oppenheimer), restructuring (10% workforce cuts at Shenandoah, Cboe), and margin compression (-20bps at Colgate). Capital allocation trends are shareholder-friendly with 7 companies raising dividends (Oppenheimer +11%, TPG $0.59/share) and active buybacks (Verizon $2.5B Q1, Cboe $45M Q1, Ryan $40M Q1), signaling management conviction amid AUM/AUC growth (BNY Mellon +12% AUC/A to $59.4T). M&A activity accelerates (UWM revised Two Harbors offer, Stock Yards/Field & Main close, Burke & Herbert/LINKBANCORP), while refinancings lower costs (Herbalife $45M annual savings). Guidance changes lean positive (Cboe raised organic revenue to mid-teens, Civeo revenue to $675-700M), but telecom/industrials show declines (Wabash sales -20% YoY, Shenandoah net loss widened). Portfolio-level: Financials outperform (avg +18% rev YoY vs industrials +5%), with Nasdaq compliance resolutions (Soluna, Onfolio) adding stability; overall sentiment mixed but actionably bullish on efficiency gains and catalysts.

26 high priority 24 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 01, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Discretionary stream (broadly including adjacent financials, industrials, and REITs), Q1 2026 results reveal mixed performance with average revenue growth of ~11% YoY among 18 reporting firms (e.g., Cboe +29%, Cinemark +19%, Boston Scientific +12%), but 10/18 showed profitability declines averaging -35% YoY due to margin compression (-150 bps avg in 7 cases) and rising costs. Capital allocation remains shareholder-friendly, with buybacks totaling >$150M (Fulgent $40M, Cboe $73M incl. plans, CubeSmart $33M) and dividend increases (Federal Realty +3%, BNY Mellon steady 24% payout). Guidance changes are net positive: raises at Cboe (organic revenue to mid-teens), Federal Realty (FFO $7.46-$7.55), lowered expenses at Cboe/Smurfit offsets. M&A/refinancing activity boosts flexibility (Herbalife $45M annual savings, Burke & Herbert merger to 100 branches), while 12 13F filings highlight institutional conviction in consumer staples/tech proxies like Yum China ($555M BLS), Walmart ($64M FourPath). Cash flow trends weak (9/15 negative OCF), signaling near-term risks amid workforce cuts (Cboe -20%) and compliance issues (Greenidge Nasdaq). Portfolio-level: outperformance in exchanges/REITs vs. homebuilders/packaging underperformance, with catalysts from earnings calls and mergers.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 01, 2026

Across the 50 filings in the USA S&P 500 Healthcare intelligence stream (with diverse sector exposure including financials, biotech, and industrials), Q1 2026 results reveal robust revenue growth averaging +40% YoY in reporting companies (e.g., Moderna +260%, SCI Engineered +133%, Cinemark +18.9%), but persistent negative operating cash flows in 8/15 Q1 filers (avg -$100M, e.g., Ryan -$167M, Cinemark -$20M) signal working capital strains despite margin improvements in 6 cases (e.g., Newell gross margin +100 bps to 33.1%). Capital allocation leans shareholder-friendly with buybacks totaling >$200M (Ryan $40M, Civeo $14M, Virtu $56M, Truist $1.1B shares) and steady dividends (BNY 24% payout, Alerus +5% to $0.21), while M&A activity (Boston Scientific Nalu $588M, Burke & Herbert merger) bolsters healthcare and financial footprints. Healthcare standouts like Boston Scientific (+11.6% sales YoY, +99% net income) and Moderna (+260% revenue) contrast mixed sentiment (12/20 mixed), with forward guidance raises in Newell (FY sales flat to +2%) and Civeo (FY rev $675-700M) providing near-term catalysts amid insider-agnostic filings. Portfolio-level trends show financials outperforming (avg net income +40% YoY in banks like Glacier +50.5%, Truist +17%) vs. consumer/industrials cash burn risks, implying rotation opportunities into growth healthcare names. Overall, bullish growth momentum tempers by liquidity concerns, favoring buyback-heavy firms with raised guidance.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 01, 2026

Across 31 filings from the USA S&P 500 Technology stream (broadly including adjacent sectors like telecom and software), Q1 2026 results show mixed performance with 12/17 quarterly reporters posting YoY revenue growth averaging +11% (led by Apple +16.5%, Cadence +19%, Iradimed +12.6-13%), but profitability pressures evident in 8/17 cases with net losses widening or income declining (e.g., Shentel net loss $15.8M vs $9.1M, Smurfit operating profit -54%). Acquisitions drove asset growth and cash burn in Cadence (-53% cash QoQ), Verizon (-56% cash QoQ), and Atmus (debt +$455M), while capital returns remained robust via buybacks (Apple $36B 6-mo, Verizon $2.5B Q1, Cadence $200M Q1) and dividends (Iradimed $0.20/sh, Atmus $0.055/sh). Forward guidance was largely reaffirmed (Shentel rev $370-377M, Iradimed FY $91-96M, Atmus sales $1.945-2.015B), but risks from restatements (Ducommun overstating NI $9.8M FY24) and workforce cuts (Shentel 10%) signal caution. Sentiment is mixed/neutral overall (20/31 mixed/neutral), with tech outliers like Apple and Cadence showing strength amid sector capex intensity. Portfolio-level trends point to revenue resilience but margin compression in 6/10 key filers (-150bps avg where reported) and ongoing M&A for growth.

17 high priority 14 medium 31 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 30, 2026

Across 45 filings dominated by Q1 2026 results and institutional 13Fs, S&P 500 Technology peers like Apple and KLA showcased robust growth with Apple posting record Q2 FY2026 revenue of $111.2B (+17% YoY) and Services +16% YoY, while KLA reported Q3 FY2026 revenue +11.5% YoY to $3.4B; however, broader filings reveal mixed sector trends with average revenue growth ~8-10% YoY in reporting companies but frequent margin compressions (e.g., -270bps at BMS, -2.4% NIM at NorthEast). Institutional 13Fs from Munich Re ($4B portfolio top NVDA/MSFT), Arista Wealth (AAPL/SPY heavy), and others confirm sustained overweight in mega-cap tech amid diversified holdings. Capital allocation trends favor shareholders with Apple's +4% dividend hike to $0.27/share and $100B buyback authorization, KLA's $1.72B repurchases, First Northern's 5% stock dividend +6% repurchase, and multiple quarterly dividends (e.g., Esquire $0.20/share). Forward guidance largely stable or upbeat (Weave FY rev $275-278M, Smurfit EBITDA $5-5.3B reaffirmed), but outliers like NCS Multistage's net loss signal caution. Portfolio-level: 7/12 growth reporters beat YoY revenue (avg +12%), but 6/10 saw margin/FFO declines; tech outliers outperform with ROE/ROA strength. Key implication: Favor tech leaders amid capital returns surge, monitor June AGMs for governance catalysts.

17 high priority 28 medium 45 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 30, 2026

Across 50 SEC filings from NASDAQ-100 constituents and related entities for the period ending April 30, 2026, Q1 2026 results reveal robust revenue growth in megacap tech (Amazon +16.6% YoY, Alphabet +21.8% YoY, Meta +33.1% YoY, Apple +17% YoY) averaging 22% YoY, offsetting margin pressures and declines in industrials/healthcare (Acadia NI -51% YoY, CPKC rev -2% YoY, Smurfit NI -83.5% YoY). Capital allocation trends emphasize shareholder returns with aggressive buybacks (CCC $400M, CPKC $680M Q1, Apple +$100B authorization) and dividends (Apple +4%, First Northern 5% stock div), alongside biotech fundraising (Intellia $194.6M extending runway to 2028, Immunic $200M). Mixed sentiment dominates (24/50 filings), driven by strong top-line but capex surges (Meta +46.7% YoY, Amazon +76.7% YoY) and exec changes (CCC CFO departure, PayPal reorg). Forward-looking catalysts cluster in June (10+ annual meetings, e.g., ImmunityBio June 9, Intellia June 9) and H2 2026 (Phase 3 data, approvals). Institutional 13G/13F filings confirm passive stakes in tech leaders (Vanguard 7.49% NFLX, 7.48% MSFT, 5.61% TSLA), signaling stability. Portfolio-level trends show 12/18 reporting companies with YoY revenue growth >10%, but 7/12 with EBITDA/operating margin contraction averaging -200bps, highlighting investment phase risks/opportunities.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 30, 2026

Across 50 filings from the USA S&P 500 Financials stream (including banks, insurers, asset managers, and related), Q1 2026 quarterly reports dominate with 70% showing revenue growth averaging +11% YoY (e.g., Hippo +10%, Southside NII +7.1%, First Northern NII +7.9%), but profitability is mixed as 55% reported net income declines or losses due to opex surges (avg +20% YoY), impairments, and margin compression (e.g., Pilgrim's EBITDA margin -520 bps to 6.8%). Financial institutions like banks (First Northern NI +61% YoY, Southside +8%) and insurers (Hippo turnaround to $7.1M NI from -$47.7M loss, Cigna adj inc +12%) outperform non-financial outliers, signaling sector resilience amid deposit softness and NIM stability. Capital allocation remains shareholder-friendly with buybacks (e.g., Southside authorized 6%, Moelis $117M) and dividends (e.g., First Northern 5% stock dividend), though cash flows weaken QoQ in 60% of cases (avg -15%). Forward-looking guidance is raised in key names (Hippo GWP to $1.45-1.525B, Cigna FY adj EPS $30.35+), building a positive catalyst calendar into H2 2026. Portfolio-level trends highlight relative outperformance in regional banks (ROAA avg 1.2% up YoY) vs broader pressures from impairments and capex, implying tactical overweight in profitable financials with strong liquidity (net leverage <2x). Overall sentiment mixed (65% of filings), with actionable alpha in insurer turnarounds and bank deposit betas.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 30, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Staples stream (broadly including adjacent sectors like food/beverages, household products, and related), Q1 2026 results reveal robust revenue growth averaging +25% YoY in 12/18 reporting companies (e.g., Angel Studios +143%, Eli Lilly +56%, Glaukos +41%), driven by pricing power and volume in select areas, though staples volumes declined (Molson Coors -2.9%, Altria cigarettes -2.4% adjusted, Hershey -2 points). Margin trends mixed with expansions in 7/15 (e.g., Angel +300bps to 62%, Iron Mountain +20bps to 36.6%) offset by compressions (Hershey salty snacks -530bps, UMC -590bps gross). Capital returns strong via buybacks ($2.4B aggregate noted, e.g., CCC $400M, Altria $280M) and dividends (Altria $1.8B, Hershey reaffirmed), but cash piles declined QoQ in 10/15 (avg -20%). Guidance raised in 6 key names (Eli Lilly rev to $82-85B, Iron Mountain EBITDA +14%, Garrett sales to $3.6-3.9B), signaling conviction amid mixed sentiment (14/20 mixed). Portfolio-level theme: Pricing offsets volume weakness in staples; watch biotech/health adjacents for outsized growth. Critical implication: Favor raised-guidance leaders for near-term upside, hedge volume risks in beverages/tobacco.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 30, 2026

Across 50 SEC filings from S&P 500 Industrials and adjacent sectors for Q1 2026 (period ending ~March 31, 2026), mixed sentiment prevails in 70% of material reports, with 18/25 key quarterly earners showing average revenue growth of 12% YoY (range -30% to +27%) but margin compression in 14 cases averaging -150 bps YoY due to cost inflation, impairments, and weather disruptions. Industrials like Caterpillar (+22% sales), Trane Technologies (+6% revenues, record backlog +30%), and L3Harris (+12% revenue, backlog $40.7B) highlight robust demand in construction, HVAC, and defense, offset by softer Resource Industries and EMEA. Capital allocation trends strongly favor shareholders with $12B+ in buybacks/dividends across 15 firms (e.g., Caterpillar $5B, Newmark 10.4M shares), while M&A activity surges (e.g., Pioneer Bancorp acquisitions, Martin Marietta New Frontier deal). Guidance raised in 9 companies (e.g., Trane to 9.5% growth, L3Harris EPS +$0.10), signaling conviction amid geopolitical risks. Banks exhibit NIM stability (avg +5 bps QoQ) but deposit/loan volatility; non-industrials like Alphabet (+22% revenue) provide relative outperformance benchmarks. Portfolio implication: overweight defensive industrials with strong backlogs/book-to-bills >1.2x, monitor margin recovery catalysts.

12 high priority 38 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 30, 2026

Across 20 SEC filings from the USA S&P 500 Energy stream (including contextual non-energy for completeness), Q1 2026 results show mixed performance with average revenue growth of ~14% YoY where reported (Valero +7%, CommScope +21.6%, SunCoke +4%, Southern Copper +36.2%, offset by ConocoPhillips -5%), but profitability trends divergent: strong turnarounds (Valero from loss to $1.26B NI) contrasted by declines (Conoco NI -23%, SunCoke op inc -85%). Capital allocation remains shareholder-friendly, with $ billions returned via dividends/buybacks (Conoco $2B Q1, Valero $923M Q1 treasury+div, CommScope $10/share special dist). M&A/divestitures drive gains (CommScope $5.3B discontinued ops gain from CCS sale, RUCKUS to Belden $1.846B; SunCoke Phoenix acquisition adding $63M rev). Energy sector faces production headwinds (Conoco -3% YoY to 2.3MMBOED, Ecopetrol slight dip) but stable guidance (SunCoke FY adj EBITDA $230-250M reaffirmed, Conoco FY prod 2.295-2.325MMBOED). Sentiment mixed overall (9/20 mixed), with outliers in refining/metals shining; portfolio implication: favor capital returners amid volatile ops metrics.

10 high priority 10 medium 20 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 30, 2026

Across 50 SEC filings for the USA Dow Jones 30 intelligence stream (period April 30, 2026), Q1 2026 results dominate with 25+ earnings reports showing aggregate revenue growth of ~12% YoY (e.g., Caterpillar +22%, Quanta +26%, Merck +5%) but mixed profitability due to one-offs like impairments (Bausch $1.4B goodwill) and R&D spikes (Viking +263%). Margin trends reveal compression in 14/30 high-materiality filers (avg -150 bps, e.g., CNH Ag 440 bps drop), offset by expansions in banks (Pioneer NIM +9 bps) and insurers (Hippo combined ratio -60 pts). M&A activity surges with 12+ deals (e.g., Nvni 7 acquisitions, Pioneer 3), while capital allocation favors returns (18/50 announce buybacks/dividends, e.g., Southside $0.36 div, Quanta raised guidance). Guidance raised in 10/20 cases (e.g., Hippo GWP +$25-75M, Indivior rev +$90-90M), signaling resilience amid macro headwinds. Biotech fundraises extend runways (Intellia to 2028), but ongoing losses flag cash burn risks. Portfolio implication: overweight industrials (backlogs $48B Quanta), monitor banks for NIM/expenses, avoid high-impairment pharma.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 30, 2026

Across 50 SEC filings from S&P 500 Consumer Discretionary (retail, auto, hospitality, entertainment), Q1 2026 results show robust revenue growth averaging 8-12% YoY in key reporters like Amazon (+16.6%), Meta (+33.1%), Ford (+6.4%), Chipotle (+7.4%), and Wayfair (+7.4%), driven by pricing, volume, and services, but offset by margin compression (e.g., Chipotle ops income -17.1%, Builders gross margin -220 bps) from labor/food costs and capex surges (Amazon +76.7% YoY, Meta +46.7%). Capital allocation remains shareholder-friendly with aggressive buybacks (Chipotle $755M, Hilton $150M, PBF $9M) and dividends (e.g., Ford cut but others up), alongside positive financing (Bob's +$75M revolver to $200M, FTAI Aviation to $2.025B) and M&A (MARA $1.5B acquisition, FTAI sale $1.52B). Mixed sentiment prevails (28/50 mixed), with bullish expansions (AITX hospitality, Amazon services +20.2%) contrasting deteriorations (Smurfit net income -83.5%, OneWater rev -8.5%); forward guidance mostly reaffirmed or raised (Hilton EBITDA to $1.225-1.265B, Diebold full-year outlook). Insider conviction mixed (Tesla Musk 413M shares held, Apollo stable holdings), no major sells flagged. Portfolio implication: Favor high-growth retail/tech like Amazon/Meta over cyclical auto/construction amid cost pressures; watch Q2 catalysts for margin recovery.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 30, 2026

Across 50 SEC filings from the USA S&P 500 Healthcare stream (though including cross-sector noise), Q1 2026 results show mixed performance with 12/20 earnings reporters posting YoY revenue growth averaging +20% (led by Eli Lilly +56%, Newmark +27%), but 8/20 facing margin compression or one-off losses (avg -150bps EBITDA margins in mixed filers like Merck, Baxter). Healthcare standouts include Eli Lilly's blockbuster-driven surge (Mounjaro +125% YoY) and Cigna's raised FY2026 EPS guidance to $30.35+, contrasting softer organic growth in Baxter (-1%) and Pacira's reiterated flat outlook; non-healthcare like Newmark and LPL Financial highlight capital return strength via buybacks/dividends. Forward-looking catalysts cluster in May-Jun 2026 (Merck Terns acquisition close, multiple AGMs), with 6/50 flagging raised guidance and 7/50 noting buybacks totaling >$2B (e.g., CPKC $680M Q1). Insider activity sparse (mostly neutral 13Fs showing institutional conviction in tech/health ETFs), but capital allocation trends bullish (dividend hikes in 5/50, e.g., Newmark to $0.06). Portfolio implication: overweight pharma growth names amid efficiency gains (Cigna SG&A -100bps), monitor margin pressures and M&A integration risks.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 29, 2026

Across 43 filings from S&P 500 Technology stream (with broader exposure via 13Fs and proxies), dominant themes include robust cloud/AI growth in Microsoft (revenue +18% YoY, Azure +40%, AI run-rate +123% to $37B) contrasting mixed semiconductor results like Qualcomm's -3% YoY revenue amid handset weakness but +38% Automotive. Period-over-period trends show 4/6 key tech firms with double-digit YoY revenue growth (avg +14%), margin stability or expansion in leaders like KLA (+11.8% non-GAAP EPS), aggressive capital returns ($10.2B Microsoft, $20B new Qualcomm buyback, $7B KLA), and raised guidance (SBA FY AFFO/share, KLA Q4 revenue). Institutional 13Fs highlight sustained tech conviction (R Squared $4.78B Apple/$2.62B MSFT, Vanguard 7.48% Apple). Non-tech filings reveal dividend hikes (CPKC +17.5%, KLA to $2.30, ACNB $0.42+$0.50 special) but declines elsewhere (Cumulus -12.2% revenue, Oxford NAV -22% QoQ). Portfolio implications: overweight AI/cloud leaders amid sector rotation; monitor semiconductor recovery and bankruptcy risks in adjacent media.

12 high priority 31 medium 43 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 29, 2026

Across 38 filings from NASDAQ-100 and related constituents, Big Tech dominates with robust revenue growth (e.g., Meta +33% YoY, Alphabet +22% YoY, Microsoft +18% YoY, Amazon +17% YoY) fueled by AI, cloud, and ads, though offset by surging capex (Meta $125-145B FY26, up from prior) and flat margins; cyclical sectors show mixed results with declines in handsets (Qualcomm -13% YoY) and media (Cumulus -12.2% YoY amid bankruptcy). Period-over-period trends reveal 12/20 earnings reporters posting YoY revenue growth averaging +15%, but margins compressed in 8 cases (avg -50 bps) due to opex/investments; guidance raised in 6 firms (ADP to 6-7% rev, SBA AFFO $11.93-12.38). Capital allocation remains shareholder-friendly with dividend hikes (CPKC +17.5%, Alphabet +5%), massive buybacks (Qualcomm new $20B auth, MSFT $10.2B returned), and compliance wins (MultiSensor AI Nasdaq regain). Portfolio-level patterns highlight AI-driven outperformance in cloud (Azure +40%, AWS +28%, Google Cloud +63%) vs weakness in traditional media/auto handsets; implications favor long tech/AI exposure but monitor capex drag and bankruptcy spillovers.

12 high priority 26 medium 38 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 29, 2026

Across 50 SEC filings from the USA S&P 500 Financials stream (including banks, insurers, fintech, and adjacent sectors), Q1 2026 results dominate with 65% showing YoY revenue growth averaging +15% (e.g., Visa +17%, Robinhood +15%, Central Pacific deposits +1.6%), but margins compressed in 55% of cases by avg -50 bps due to higher opex and provisions. Financials exhibit stable balance sheets with deposit/asset growth (Central Pacific assets +1.2% QoQ) and robust capital returns (buybacks/dividends in 40% of filings, totaling >$3B across entities like SiteOne $20M, News Corp $1B program). M&A activity surges with 6 deals (Woori share exchange Aug 11, Mission-Calavo July close, Biogen-Apellis), while guidance mixed: 30% raised (Constellium EBITDA to $900-940M), 20% cut (Humana EPS to $8.36, GE HealthCare margin to 15.4-15.7%). Insider activity absent in data, but management conviction via buybacks strong; sentiment mixed (45% mixed, 25% positive). Portfolio trend: Financials resilient amid NIM stability (Central Pacific 3.53%), but insurers face benefit ratio pressures (Humana 89.4%). Key implication: Favor banks/fintech with deposit growth and capital returns over insurers with guidance cuts; watch Q2 catalysts for margin recovery.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 29, 2026

Across 50 SEC filings from diverse sectors (limited true S&P 500 Consumer Staples exposure, e.g., Philip Morris), Q1 2026 results dominate with mixed sentiment in 70% of cases, showing average revenue growth of +18% YoY in 14/20 reporters (e.g., Welltower +38%, Glaukos +41%, Lemonade +71%) offset by net losses in 9/15 cases and margin volatility. Key trends include EBITDA improvements (Constellium +93%, Delek Logistics +7.4%) and guidance raises in 5 companies (Constellium to $900-940M EBITDA, Glaukos to $620-635M sales, Ford to $8.5-10.5B EBIT), alongside capital returns via dividends (10+ firms, e.g., Delek Logistics +1.8%) and buybacks (Clarivate $18.1M, Lakeland 337k shares). Declines evident in solar (JinkoSolar rev -29% YoY, margins to 2.2%) and tech/services (Clarivate -1.4%, Teladoc -2%). Debt management proactive (Clarivate retired $143M at 10% discount, no debt at Glaukos), but legal risks (Atkore $136.5M settlement) and delistings (Sangamo) loom. Portfolio implications: Favor outperformers with raised guidance and FCF positivity for near-term alpha; caution on loss-widening names amid macro pressures; monitor June AGMs and late-April earnings calls for catalysts.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 29, 2026

Across 50 SEC filings from diverse sectors (labeled S&P 500 Industrials but including pharma, energy, banks, and industrials), Q1 2026 results reveal broad revenue growth averaging +10% YoY in 28/35 reporting companies (e.g., Tradeweb +21%, GE HealthCare +7%, IDEX +9%), driven by pricing, acquisitions, and segment strength, though organic growth lagged at +3-5% in many. Margins showed mixed trends with 18/35 companies reporting compression averaging -80 bps (e.g., Stanley Black & Decker adj EBITDA -50 bps, GE HealthCare adj EBIT -150 bps), offset by expansions in outliers like Lemonade gross margin to 39% (+YoY). Guidance was raised by 12 companies (e.g., Bunge adj EPS to $9.00-$9.50 from $7.50-$8.00, IDEX organic sales to 3-4%), signaling management confidence amid M&A (Biogen-Apellis, GE-Intelerad) and capital returns ($76M IDEX buybacks, $57M Prosperity repurchases). Capital allocation leaned toward dividends/buybacks in 15 filings (e.g., Delek Logistics +1.8% distribution), with divestitures bolstering balance sheets (Stanley $1.6B net CAM proceeds). Portfolio-level patterns include 7/10 industrials (Stanley, IDEX, Generac) beating organic growth expectations, but energy/utilities mixed (OGE net income -20% YoY). Key implications: tactical buys in guidance-raisers, caution on margin squeezes; catalyst-rich with FDA PDUs and earnings calls imminent.

18 high priority 32 medium 50 total filings